Trials / Completed
CompletedNCT06281158
A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
A Study of the Pharmacokinetics of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Denali Therapeutics Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1, open-label, nonrandomized, single-dose study in healthy male participants to investigate the absorption, metabolism and excretion of DNL343.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-DNL343 | Single dose |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2024-04-30
- Completion
- 2024-04-30
- First posted
- 2024-02-28
- Last updated
- 2024-06-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06281158. Inclusion in this directory is not an endorsement.